UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
2003, Volume 42, Issue 14, 30
Melphalan, pharmacokinetics | Vinblastine, pharmacokinetics | Cytarabine, pharmacokinetics | Antimetabolites, pharmacokinetics | Gemcitabine, pharmacodynamics | Vinca alkaloids, pharmacodynamics | Fluorouracil, pharmacokinetics | Ifosfamide, pharmacodynamics | Methotrexate, pharmacokinetics | Topotecan, pharmacodynamics | Capecitabine, pharmacodynamics | Irinotecan, pharmacokinetics | Vinca alkaloids, pharmacokinetics | Alkylating agents, pharmacokinetics | Chlorambucil, pharmacokinetics | Cyclophosphamide, pharmacodynamics | Vincristine, pharmacokinetics | Carboplatin, pharmacodynamics | Fludarabine, pharmacodynamics | Cisplatin, pharmacokinetics | Vinorelbine, pharmacodynamics | Capecitabine, pharmacokinetics | Platinum complexes, pharmacokinetics | Topotecan, pharmacokinetics | Cytarabine, pharmacodynamics | DNA topoisomerase inhibitors, pharmacodynamics | Chlorambucil, pharmacodynamics | Fluorouracil, pharmacodynamics | Fludarabine, pharmacokinetics | Cyclophosphamide, pharmacokinetics | Antimetabolites, pharmacodynamics | Gemcitabine, pharmacokinetics | Melphalan, pharmacodynamics | Oxaliplatin, pharmacokinetics | Vinblastine, pharmacodynamics | Vinorelbine, pharmacokinetics | Cisplatin, pharmacodynamics | Vincristine, pharmacodynamics | Oxaliplatin, pharmacodynamics | Irinotecan, pharmacodynamics | Ifosfamide, pharmacokinetics | Methotrexate, pharmacodynamics | Alkylating agents, pharmacodynamics | Platinum complexes, pharmacodynamics | Carboplatin, pharmacokinetics | Elderly | DNA topoisomerase inhibitors, pharmacokinetics | Cancer | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Drug Interactions | Antineoplastic Agents - adverse effects | Humans | Aged, 80 and over | Aging | Aged | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Frail Elderly | Patient Compliance | Neoplasms - drug therapy | Randomized Controlled Trials as Topic | Index Medicus
Book Review
11/2000, Volume 39, Issue 5, 23
NSC 95580, pharmacokinetics | Teniposide, pharmacokinetics | Topotecan, pharmacokinetics | Iododoxorubicin, pharmacokinetics | Fluorouracil, pharmacokinetics | Cyclophosphamide, pharmacokinetics | Menogaril, pharmacokinetics | Research and development | Paclitaxel, pharmacokinetics | Epirubicin, pharmacokinetics | Etoposide, pharmacokinetics | Antineoplastics, pharmacokinetics | Busulfan, pharmacokinetics | Docetaxel, pharmacokinetics | Idarubicin, pharmacokinetics | Carboplatin, pharmacokinetics | Cisplatin, pharmacokinetics | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Busulfan - pharmacokinetics | Cisplatin - pharmacokinetics | Area Under Curve | Humans | Carboplatin - administration & dosage | Etoposide - administration & dosage | Carboplatin - pharmacokinetics | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cisplatin - administration & dosage | Animals | Fluorouracil - administration & dosage | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Antineoplastic Agents - pharmacokinetics | Fluorouracil - pharmacokinetics | Etoposide - pharmacokinetics | Index Medicus
Book Review
Current medicinal chemistry, ISSN 0929-8673, 01/2017, Volume 24, Issue 2, pp. 193 - 214
Cytotoxicity | Chemotherapy | Metal organic frameworks (MOFs) | Loading | Release | Cancer | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Humans | Succinates - pharmacokinetics | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Organoplatinum Compounds - pharmacology | Drug Carriers | Nanoparticles | Fluorouracil - administration & dosage | Organoplatinum Compounds - pharmacokinetics | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacokinetics | Doxorubicin - administration & dosage | Camptothecin - pharmacokinetics | Busulfan - pharmacokinetics | Polymers - chemical synthesis | Doxorubicin - pharmacokinetics | Organometallic Compounds - chemical synthesis | Topotecan - pharmacokinetics | Cell Line, Tumor | Topotecan - administration & dosage | Organometallic Compounds - chemistry | Polymers - chemistry | Porosity | Fluorouracil - pharmacokinetics | Succinates - pharmacology | Drug carriers | Drug delivery systems | 5-Fluorouracil | Biodegradability | Metals | Polyelectrolytes | Drug delivery | Doxorubicin | Biomedical materials | Catalysis | Methotrexate | Polymers | Metal ions | Biodegradation | Medical imaging | Pharmacology | Tamoxifen | Cisplatin | Side effects | In vivo methods and tests | Liposomes | Pharmacokinetics | Metal-organic frameworks
Journal Article
Molecular pharmacology, ISSN 0026-895X, 01/2007, Volume 71, Issue 1, pp. 240 - 9
ATP Binding Cassette Transporter, Subfamily G, Member 2 | Cell Line | Rabbits | Humans | ATP-Binding Cassette Transporters/metabolism | Topotecan/pharmacokinetics | Mitoxantrone/pharmacokinetics | Animals | Antineoplastic Agents/pharmacokinetics | Biological Transport | Stilbenes/pharmacokinetics | Folic Acid/pharmacokinetics | Liver/metabolism | Dogs | Resveratrol | Cell Line, Tumor | Methotrexate/analogs & derivatives | Female | Kinetics | Neoplasm Proteins/metabolism | Breast Neoplasms/metabolism | Hydrogen-Ion Concentration | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Liver - metabolism | Methotrexate - pharmacokinetics | Neoplasm Proteins - metabolism | Folic Acid - pharmacokinetics | Breast Neoplasms - metabolism | Topotecan - pharmacokinetics | ATP-Binding Cassette Transporters - metabolism | Stilbenes - pharmacokinetics | Antineoplastic Agents - pharmacokinetics | Mitoxantrone - pharmacokinetics | Methotrexate - analogs & derivatives | Index Medicus
Journal Article
2005, Volume 44, Issue 1, 31
Mafosfamide, pharmacokinetics | Cytarabine, pharmacokinetics | Topotecan, pharmacokinetics | Diaziquone, pharmacokinetics | Methotrexate, pharmacokinetics | Research and development | Corticosteroids, pharmacokinetics | Etoposide, pharmacokinetics | Antineoplastics, pharmacokinetics | Bleomycin, pharmacokinetics | Nimustine, pharmacokinetics | Mercaptopurine, pharmacokinetics | Meningitis, treatment | Thiotepa, pharmacokinetics | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Injections, Spinal | Infusion Pumps, Implantable | Drug Administration Schedule | Humans | Injections, Intraventricular | Metabolic Clearance Rate | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Animals | Meningeal Neoplasms - cerebrospinal fluid | Meningeal Neoplasms - drug therapy | Cerebrospinal Fluid - metabolism | Adolescent | Adult | Antineoplastic Agents - pharmacokinetics | Child | Meningeal Neoplasms - secondary | Index Medicus
Book Review
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 12/2020, Volume 86, Issue 6, pp. 829 - 840
Crizotinib | Oncology | Phase 1 | Pediatric | Chemotherapy combinations | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Pediatrics | Toxicity | Cytotoxicity | Topotecan | Pharmacology | Exposure | Bioavailability | Doxorubicin | Vincristine | Lymphoma | Patients | Consortia | Microspheres | Cyclophosphamide | Chemotherapy | Palatability | Anaplastic large-cell lymphoma | Children | Safety | Solid tumors | Pharmacokinetics | Tumors | Index Medicus
Journal Article
Drug safety, ISSN 0114-5916, 2006, Volume 29, Issue 3, pp. 209 - 230
Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Camptothecin - adverse effects | Podophyllotoxin - pharmacology | Camptothecin - therapeutic use | Podophyllotoxin - adverse effects | Humans | Enzyme Inhibitors - pharmacology | Podophyllotoxin - therapeutic use | Topoisomerase I Inhibitors | Neoplasms - enzymology | Enzyme Inhibitors - therapeutic use | Neoplasms - drug therapy | Topoisomerase II Inhibitors | Antineoplastic Agents, Phytogenic - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Camptothecin - pharmacology | Antineoplastic Agents, Phytogenic - adverse effects | Index Medicus
Journal Article